Compare PPCB & BJDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPCB | BJDX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | Australia | United States |
| Employees | 2 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.0M |
| IPO Year | N/A | 2021 |
| Metric | PPCB | BJDX |
|---|---|---|
| Price | $0.10 | $1.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.1M | 16.6K |
| Earning Date | 05-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $249,040.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.63 |
| 52 Week High | $10.69 | $4.17 |
| Indicator | PPCB | BJDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.65 | 49.81 |
| Support Level | N/A | $1.73 |
| Resistance Level | $0.13 | $2.10 |
| Average True Range (ATR) | 0.01 | 0.12 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 21.51 | 42.19 |
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.